Estradiol Supplement or Induced Hypertension May Attenuate the Angiotensin II Type 1 Receptor Antagonist-Promoted Renal Blood Flow Response to Graded Angiotensin II Administration in Ovariectomized Rats.
Journal
Journal of the renin-angiotensin-aldosterone system : JRAAS
ISSN: 1752-8976
Titre abrégé: J Renin Angiotensin Aldosterone Syst
Pays: England
ID NLM: 100971636
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2022
revised:
05
03
2022
accepted:
03
06
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Estrogen replacement therapy (ERT) and hypertension may influence females' renin-angiotensin system (RAS) and its components. The angiotensin II (Ang II) type 1 receptor (AT1R) antagonist (losartan) may promote renal blood flow (RBF), and it is widely used in the clinic to control hypertension. The main objective of this study was the effects of estradiol or induced hypertension on RBF response to Ang II in losartan-treated ovariectomized (OVX) rats. Two groups of OVX rats were treated with placebo (group 1) and estradiol (group 2) for period of four weeks, and another group of OVX rats was subjected to induce hypertension by two-kidney one clip (2K1C) model (group 3). All the groups were subjected to the surgical procedure under anesthesia, and AT1R was blocked by losartan. RBF and renal vascular resistance (RVR) responses to Ang II administration were determined and compared. Mean arterial (MAP) and renal perfusion (RPP) pressures in group 3 and uterus weight (UT) in group 2 were significantly more than other groups ( Losartan prescription in some conditions such as hypertension or ERT could worsen RBF and RVR responses to Ang II.
Sections du résumé
Backgrounds
UNASSIGNED
Estrogen replacement therapy (ERT) and hypertension may influence females' renin-angiotensin system (RAS) and its components. The angiotensin II (Ang II) type 1 receptor (AT1R) antagonist (losartan) may promote renal blood flow (RBF), and it is widely used in the clinic to control hypertension. The main objective of this study was the effects of estradiol or induced hypertension on RBF response to Ang II in losartan-treated ovariectomized (OVX) rats.
Methods
UNASSIGNED
Two groups of OVX rats were treated with placebo (group 1) and estradiol (group 2) for period of four weeks, and another group of OVX rats was subjected to induce hypertension by two-kidney one clip (2K1C) model (group 3). All the groups were subjected to the surgical procedure under anesthesia, and AT1R was blocked by losartan. RBF and renal vascular resistance (RVR) responses to Ang II administration were determined and compared.
Results
UNASSIGNED
Mean arterial (MAP) and renal perfusion (RPP) pressures in group 3 and uterus weight (UT) in group 2 were significantly more than other groups (
Conclusion
UNASSIGNED
Losartan prescription in some conditions such as hypertension or ERT could worsen RBF and RVR responses to Ang II.
Identifiants
pubmed: 35859805
doi: 10.1155/2022/3223008
pmc: PMC9270140
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Receptor, Angiotensin, Type 1
0
Angiotensin II
11128-99-7
Estradiol
4TI98Z838E
Losartan
JMS50MPO89
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3223008Informations de copyright
Copyright © 2022 Samira Choopani and Mehdi Nematbakhsh.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Am J Physiol Renal Physiol. 2002 Jan;282(1):F19-25
pubmed: 11739108
Cardiovasc Res. 2002 Feb 15;53(3):688-708
pubmed: 11861040
Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R159-65
pubmed: 22031787
Circulation. 2012 Apr 3;125(13):1635-42
pubmed: 22379110
Hypertension. 1995 Jun;25(6):1232-7
pubmed: 7768567
Hypertension. 2002 Feb;39(2 Pt 2):316-22
pubmed: 11882566
Am J Physiol Cell Physiol. 2006 Feb;290(2):C420-6
pubmed: 16176966
Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1220-6
pubmed: 18287217
Hypertension. 2008 Oct;52(4):666-71
pubmed: 18711010
N Engl J Med. 1999 Jun 10;340(23):1801-11
pubmed: 10362825
Physiol Rev. 2006 Jul;86(3):747-803
pubmed: 16816138
Am J Physiol. 1996 Dec;271(6 Pt 2):H2306-12
pubmed: 8997287
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F195-206
pubmed: 26823279
Am J Physiol Renal Physiol. 2000 Aug;279(2):F319-25
pubmed: 10919852
Curr Hypertens Rep. 2013 Feb;15(1):71-9
pubmed: 23180053
Sci Rep. 2020 Oct 21;10(1):17924
pubmed: 33087778
Br J Pharmacol. 2005 Feb;144(4):486-92
pubmed: 15678096
Cardiovasc Res. 2002 Feb 15;53(3):672-7
pubmed: 11861038
Pharmacol Rev. 2007 Sep;59(3):251-87
pubmed: 17878513
J Physiol. 1992;453:1-13
pubmed: 1464825
Adv Pharmacol Sci. 2015;2015:801053
pubmed: 26421009
Eur Heart J. 1999 Jul;20(14):997-1008
pubmed: 10381851
J Am Soc Nephrol. 1997 Apr;8(4):535-42
pubmed: 10495782
Nature. 2002 Jun 20;417(6891):822-8
pubmed: 12075344
Circulation. 1998 Jun 9;97(22):2197-201
pubmed: 9631868
Acta Anaesthesiol Scand. 2001 Oct;45(9):1168-75
pubmed: 11683670
Int J Vasc Med. 2021 Mar 01;2021:6643485
pubmed: 33747565
Acta Physiol Scand. 2001 Jan;171(1):99-104
pubmed: 11350268
Am J Physiol. 1997 Dec;273(6):R1908-15
pubmed: 9435644
Exp Physiol. 2008 May;93(5):648-57
pubmed: 18296494
Vascul Pharmacol. 2020 Jan;124:106600
pubmed: 31629918
Hypertension. 2004 Dec;44(6):907-12
pubmed: 15477383
Lancet. 1994 Jul 9;344(8915):101-6
pubmed: 7912348
Adv Pharmacol Sci. 2015;2015:682745
pubmed: 26681937
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Int J Hypertens. 2021 Feb 20;2021:8820646
pubmed: 33688433
Hypertension. 1999 Jan;33(1 Pt 2):366-72
pubmed: 9931131
Kidney Int. 2005 Nov;68(5):2189-96
pubmed: 16221218
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
Am J Physiol Renal Physiol. 2019 Sep 1;317(3):F670-F682
pubmed: 31339773
J Cell Mol Med. 2015 Aug;19(8):1965-74
pubmed: 25766467
Am J Physiol. 1993 Dec;265(6 Pt 2):F881-5
pubmed: 8285220
Hypertension. 1997 Sep;30(3 Pt 1):337-44
pubmed: 9314414
J Physiol. 2002 Jan 1;538(Pt 1):159-66
pubmed: 11773324
Hypertension. 2003 Aug;42(2):200-5
pubmed: 12847115
Am J Hypertens. 2014 Jun;27(6):775-82
pubmed: 24429674
Hypertension. 1999 Jan;33(1):96-101
pubmed: 9931088
Am J Physiol Renal Physiol. 2011 Mar;300(3):F749-55
pubmed: 21209009